AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses
OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today…
Spectral Design & Test (SDT) demonstrates High-Capacity SRAM Memory Compilers targeted at advanced process nodes for AI driven edge Devices